Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers

• Published in: Cancers 2021-02, Vol.13 (5), p.966
• Main Authors: Di Francia, Raffaele, Crisci, Stefania, De Monaco, Angela, Cafiero, Concetta, Re, Agnese, Iaccarino, Giancarla, De Filippi, Rosaria, Frigeri, Ferdinando, Corazzelli, Gaetano, Micera, Alessandra, Pinto, Antonio
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13050966

Cytarabine is a pyrimidine nucleoside analog, commonly used in multiagent chemotherapy regimens for the treatment of leukemia and lymphoma, as well as for neoplastic meningitis. Ara-C-based chemotherapy regimens can induce a suboptimal clinical outcome in a fraction of patients. Several studies suggest that the individual variability in clinical response to Leukemia & Lymphoma treatments among patients, underlying either Ara-C mechanism resistance or toxicity, appears to be associated with the intracellular accumulation and retention of Ara-CTP due to genetic variants related to metabolic enzymes. Herein, we reported (a) the latest Pharmacogenomics biomarkers associated with the response to cytarabine and (b) the new drug formulations with optimized pharmacokinetics. The purpose of this review is to provide readers with detailed and comprehensive information on the effects of Ara-C-based therapies, from biological to clinical practice, maintaining high the interest of both researcher and clinical hematologist. This review could help clinicians in predicting the response to cytarabine-based treatments.